/Company Directory

/

Asset Brief

PTX-100

PTX·Prescient Therapeutics·Relapsed or refractory cutaneous T-cell lymphoma (CTCL)·Phase 2·NCT06854653·Primary completion: 1 Jan 2028

Plain-language Brief

The trial in plain terms

The disease: Cutaneous T-cell lymphoma (CTCL) is a group of rare cancers in which malignant T-cells (a type of white blood cell) accumulate primarily in the skin. The most common subtypes are mycosis fungoides and Sézary syndrome. CTCL is generally considered incurable with available therapies, and patients who relapse after multiple prior treatments have limited options (per FDA Orphan Drug designation for PTX-100).
What the asset is trying to do: PTX-100 is a small molecule that inhibits an enzyme called geranylgeranyltransferase-1 (GGT-1). GGT-1 adds a lipid tag to certain proteins, including RAS-family proteins, which is required for those proteins to anchor to the cell membrane and transmit growth signals. By blocking this enzyme, PTX-100 aims to disrupt the membrane attachment and downstream signalling of these proteins. This mechanism differs from approved CTCL therapies, which include histone deacetylase (HDAC) inhibitors, retinoids, and antibody-drug conjugates that act through distinct molecular targets.
What the trial is measuring, and why it matters: The Phase 2 trial (NCT06854653) is assessing PTX-100 in patients with relapsed or refractory CTCL. The primary endpoint and full secondary endpoint set are listed in the design section below. In oncology trials at this stage, the key measures typically focus on how many patients respond to treatment and how durable those responses are, as well as the safety profile of the drug across the enrolled population.
Efficacy benchmarks in this setting: In relapsed or refractory CTCL, approved therapies have demonstrated the following efficacy in registrational studies: mogamulizumab (Poteligeo) achieved an investigator-assessed overall response rate (ORR) of 28% in mycosis fungoides and 37% in Sézary syndrome versus comparator vorinostat in the MAVORIC trial (Kim et al, Lancet Oncology 2018). Vorinostat (Zolinza), an HDAC inhibitor approved for CTCL, demonstrated an ORR of approximately 24% in a pivotal study (Olsen et al, Journal of Clinical Oncology 2007). Romidepsin (Istodax) showed an ORR of 34% in a Phase 2 CTCL study (Whittaker et al, Journal of Clinical Oncology 2010). Any efficacy figures reported from the Phase 1 study of PTX-100 (NCT03900442) were generated in a small, early-stage, single-arm context and are not statistically comparable to the controlled or larger studies underpinning those approved-therapy benchmarks.
Commercial context

Sources for this brief (7)

NCT06854653 – A Phase 2 Study of PTX-100 in Patients With Relapsed/Refractory CTCL · ClinicalTrials.gov / U.S. National Library of Medicine · accessed 15 June 2026
NCT03900442 – Phase 1 Study of PTX-100 in Patients With Advanced Malignancies With PTCL Expansion Cohort · ClinicalTrials.gov / U.S. National Library of Medicine · accessed 15 June 2026
MAVORIC trial: Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma · Lancet Oncology (Kim et al, 2018) · accessed 15 June 2026
Vorinostat in advanced cutaneous T-cell lymphoma: pivotal study · Journal of Clinical Oncology (Olsen et al, 2007) · accessed 15 June 2026
Romidepsin for cutaneous T-cell lymphoma: Phase 2 study · Journal of Clinical Oncology (Whittaker et al, 2010) · accessed 15 June 2026
Prescient Therapeutics ASX Announcements (quarterly updates, EU authorisation, investor presentation) · Australian Securities Exchange (ASX) · accessed 15 June 2026

Trial Design

Design summary

Phase: Phase 2
Design type: Open-label, multi-centre, single-arm Phase 2 study (per ClinicalTrials.gov NCT06854653).
Primary endpoint: [ TODO: fill in ]
Key secondary endpoints: [ TODO: fill in ]
Enrolment target: 115 patients (per ClinicalTrials.gov NCT06854653)
Current enrolment status: Recruiting; 8 of 16 planned global sites activated (per Prescient Therapeutics ASX announcement, March 2026 Quarterly Update)
Sites: 16 planned global sites; 8 sites activated as of the March 2026 quarterly update, including sites in Europe following EU authorisation in December 2025 (per ASX announcements).
Expected readout window: Primary completion is listed as 2028-01-01 on ClinicalTrials.gov (NCT06854653). Interim data timing has not been publicly disclosed in the provided announcements.

Class Catalyst Calendar

What's landed, what's next for PTX-100 and peers

PTX-100's own upcoming catalysts alongside class-defining historical readouts and upcoming primary completion dates in the same mechanism classes. Each event moves the broader thesis for PTX-100. Showing past 6 months and next 12 months · 11 later hidden.

ConferenceAACR Annual Meeting 2026· ChicagoApr 2026
ConferenceASCO Annual Meeting 2026· ChicagoMay 2026
Today
ConferenceESMO Congress 2026· MadridSept 2026
Anti-CCR4 Monoclonal Antibody (Mogamulizumab) and Total Skin Electron Beam Therapy (TSEB) in Patients With Stage IB-IIB Cutaneous T-Cell Lymphoma
European Organisation for Research and Treatment of Cancer - EORTC·Other·Phase 2·NCT04128072
Oct 2026CT.gov proxy
Zanubrutinib and CAR T-cell Therapy for the Treatment of Recurrent or Refractory Aggressive B-cell Non-Hodgkin's Lymphoma or Transformed Indolent B-cell Lymphoma
Northwestern University·Other·Phase 2·NCT05202782
Oct 2026CT.gov proxy
A Phase 2 Trial to Assess Safety and Efficacy of Tofacitinib 2% Cream in the Treatment of Cutaneous T-cell Lymphoma (CTCL), Stages IA, IB, and IIA
M.D. Anderson Cancer Center·Other·Phase 2·NCT06698822
Oct 2026CT.gov proxy
Study of Mogamulizumab With DA-EPOCH or CHOEP in Patients With Aggressive T-cell Lymphoma
Yale University·Other·Phase 2·NCT05996185
Nov 2026CT.gov proxy
ConferenceSITC Annual Meeting 2026· PhoenixNov 2026
JAK1 Inhibitor Golidocitnib for the Treatment of Relapsed/Refractory Indolent T/NK-cell Lymphomas
Institute of Hematology & Blood Diseases Hospital, China·Other·Phase 2·NCT06716658
Nov 2026CT.gov proxy
Mogamulizumab + Low-Dose Total Skin Electron Beam Tx in Mycosis Fungoides & Sézary Syndrome
Stanford University·Other·Phase 2·NCT04256018
Dec 2026CT.gov proxy
A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas
Dren Bio·Other·PHASE1/PHASE2·NCT05475925
Dec 2026CT.gov proxy
ConferenceASH Annual Meeting 2026· New OrleansDec 2026
Ruxolitinib Maintenance Post-Hematopoietic Stem Cell Transplant T-Cell Lymphoma
Jonathan Brammer·Other·Phase 2·NCT07356245
Dec 2026CT.gov proxy
Tafasitamab and Lenalidomide Followed by Tafasitamab and ICE as Salvage Therapy for Transplant Eligible Patients With Relapsed/ Refractory Large B-Cell Lymphoma
David Bond, MD·Other·Phase 2·NCT05821088
Dec 2026CT.gov proxy
Effectiveness of Concurrent Ultra-Low-Dose Total-Skin Electron Beam Therapy and Brentuximab Vedotin Given Quarterly Over 12 Months for Patients With Mycosis Fungoides
M.D. Anderson Cancer Center·Other·Phase 2·NCT05357794
Jan 2027CT.gov proxy
A Study to Assess the Safety, Tolerability, Efficacy, and Drug Levels of BMS-986369 (Golcadomide) in Participants With Relapsed or Refractory T-cell Lymphomas in Japan (GOLSEEK-3)
Bristol-Myers Squibb·Other·PHASE1/PHASE2·NCT06035497
Jan 2027CT.gov proxy
TOtal Skin Electron Beam Therapy (Low-dose) for Tumor Clone Eradication in Early-stage Mycosis Fungoides
Assistance Publique - Hôpitaux de Paris·Other·Phase 3·NCT05205902
Feb 2027CT.gov proxy
Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma
National Cancer Institute (NCI)·Other·PHASE2/PHASE3·NCT04799275
Mar 2027CT.gov proxy
Golcadomide and Rituximab as Bridging Therapy for Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma Before CAR T-cell Therapy
Mayo Clinic·Other·Phase 2·NCT06834373
Mar 2027CT.gov proxy
ConferenceAACR Annual Meeting 2027· OrlandoApr 2027
ConferenceASCO Annual Meeting 2027· ChicagoJune 2027
Pembrolizumab in Combination With Gemcitabine in People With Advanced Mycosis Fungoides or Sézary Syndrome
Memorial Sloan Kettering Cancer Center·Other·Phase 2·NCT04960618
July 2027CT.gov proxy
Dosing of Brentuximab Vedotin for Mycosis Fungoides, Sezary Syndrome Patients
Memorial Sloan Kettering Cancer Center·Other·Phase 2·NCT03587844
July 2027CT.gov proxy

"Sponsor guided" dates come from IR materials and earnings calls; hover for the cited source. "CT.gov proxy" dates fall back to the registry primary completion date — actual readouts typically follow by 3-6 months.

Trial design comparison

How PTX-100 reads against active peer trials

Same axes, same units. Discontinued and historical pivotal trials excluded; see Competitor Landscape below for the full set.

Trial	Sponsor	Class	Phase / Line	Design	Primary endpoint	Dosing	Key eligibility	n
PTX-100	Prescient Therapeutics	Small Molecule Other	Phase 2r/r	Open-label, multi-centre, single-arm Phase 2 study (per ClinicalTrials.gov NCT06854653).	[ TODO: fill in ]	[ TODO: fill in ]	115 patients (per ClinicalTrials.gov NCT06854653)	115
A Study to Evaluate the Efficacy and Safety of KW-0761 in Chinese Subjects With Mycosis Fungoides or Sézary Syndrome Previously Treated With Systemic Therapy

Competitor Landscape

Competing programmes by mechanism and phase

Read-across commentary attached per trial. Phase ordering preserved within each group.

OtherASX peers ›

44 activeexpand ›

KK
A Study to Evaluate the Efficacy and Safety of KW-0761 in Chinese Subjects With Mycosis Fungoides or Sézary Syndrome Previously Treated With Systemic Therapy
Phase 4
Kyowa Kirin China Pharmaceutical Co., Ltd.·Active, not recruiting·Primary completion 12 Aug 2025·NCT06285370
8 sites
23 enrolled

Curated Commentary

Third-party coverage(none curated yet)

expand ›

External analyst notes, journalism, and industry commentary cited with attribution.

No third-party coverage curated for PTX-100 yet. Broker coverage of Prescient Therapeutics is thin; named analyst notes will appear here as they become available. For now, see the company's ASX announcements and the linked sponsor / class sources elsewhere on this page.

Class Catalyst Calendar

What's landed, what's next for PTX-100 and peers

ConferenceAACR Annual Meeting 2026· ChicagoApr 2026
ConferenceASCO Annual Meeting 2026· ChicagoMay 2026
Today
ConferenceESMO Congress 2026· MadridSept 2026
Anti-CCR4 Monoclonal Antibody (Mogamulizumab) and Total Skin Electron Beam Therapy (TSEB) in Patients With Stage IB-IIB Cutaneous T-Cell Lymphoma
European Organisation for Research and Treatment of Cancer - EORTC·Other·Phase 2·NCT04128072
Oct 2026CT.gov proxy
Zanubrutinib and CAR T-cell Therapy for the Treatment of Recurrent or Refractory Aggressive B-cell Non-Hodgkin's Lymphoma or Transformed Indolent B-cell Lymphoma
Northwestern University·Other·Phase 2·NCT05202782
Oct 2026CT.gov proxy
A Phase 2 Trial to Assess Safety and Efficacy of Tofacitinib 2% Cream in the Treatment of Cutaneous T-cell Lymphoma (CTCL), Stages IA, IB, and IIA
M.D. Anderson Cancer Center·Other·Phase 2·NCT06698822
Oct 2026CT.gov proxy
Study of Mogamulizumab With DA-EPOCH or CHOEP in Patients With Aggressive T-cell Lymphoma
Yale University·Other·Phase 2·NCT05996185
Nov 2026CT.gov proxy
ConferenceSITC Annual Meeting 2026· PhoenixNov 2026
JAK1 Inhibitor Golidocitnib for the Treatment of Relapsed/Refractory Indolent T/NK-cell Lymphomas
Institute of Hematology & Blood Diseases Hospital, China·Other·Phase 2·NCT06716658
Nov 2026CT.gov proxy
Mogamulizumab + Low-Dose Total Skin Electron Beam Tx in Mycosis Fungoides & Sézary Syndrome
Stanford University·Other·Phase 2·NCT04256018
Dec 2026CT.gov proxy
A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas
Dren Bio·Other·PHASE1/PHASE2·NCT05475925
Dec 2026CT.gov proxy
ConferenceASH Annual Meeting 2026· New OrleansDec 2026
Ruxolitinib Maintenance Post-Hematopoietic Stem Cell Transplant T-Cell Lymphoma
Jonathan Brammer·Other·Phase 2·NCT07356245
Dec 2026CT.gov proxy
Tafasitamab and Lenalidomide Followed by Tafasitamab and ICE as Salvage Therapy for Transplant Eligible Patients With Relapsed/ Refractory Large B-Cell Lymphoma
David Bond, MD·Other·Phase 2·NCT05821088
Dec 2026CT.gov proxy
Effectiveness of Concurrent Ultra-Low-Dose Total-Skin Electron Beam Therapy and Brentuximab Vedotin Given Quarterly Over 12 Months for Patients With Mycosis Fungoides
M.D. Anderson Cancer Center·Other·Phase 2·NCT05357794
Jan 2027CT.gov proxy
A Study to Assess the Safety, Tolerability, Efficacy, and Drug Levels of BMS-986369 (Golcadomide) in Participants With Relapsed or Refractory T-cell Lymphomas in Japan (GOLSEEK-3)
Bristol-Myers Squibb·Other·PHASE1/PHASE2·NCT06035497
Jan 2027CT.gov proxy
TOtal Skin Electron Beam Therapy (Low-dose) for Tumor Clone Eradication in Early-stage Mycosis Fungoides
Assistance Publique - Hôpitaux de Paris·Other·Phase 3·NCT05205902
Feb 2027CT.gov proxy
Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma
National Cancer Institute (NCI)·Other·PHASE2/PHASE3·NCT04799275
Mar 2027CT.gov proxy
Golcadomide and Rituximab as Bridging Therapy for Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma Before CAR T-cell Therapy
Mayo Clinic·Other·Phase 2·NCT06834373
Mar 2027CT.gov proxy
ConferenceAACR Annual Meeting 2027· OrlandoApr 2027
ConferenceASCO Annual Meeting 2027· ChicagoJune 2027
Pembrolizumab in Combination With Gemcitabine in People With Advanced Mycosis Fungoides or Sézary Syndrome
Memorial Sloan Kettering Cancer Center·Other·Phase 2·NCT04960618
July 2027CT.gov proxy
Dosing of Brentuximab Vedotin for Mycosis Fungoides, Sezary Syndrome Patients
Memorial Sloan Kettering Cancer Center·Other·Phase 2·NCT03587844
July 2027CT.gov proxy

Trial design comparison

How PTX-100 reads against active peer trials

Same axes, same units. Discontinued and historical pivotal trials excluded; see Competitor Landscape below for the full set.

Trial	Sponsor	Class	Phase / Line	Design	Primary endpoint	Dosing	Key eligibility	n
PTX-100	Prescient Therapeutics	Small Molecule Other	Phase 2r/r	Open-label, multi-centre, single-arm Phase 2 study (per ClinicalTrials.gov NCT06854653).	[ TODO: fill in ]	[ TODO: fill in ]	115 patients (per ClinicalTrials.gov NCT06854653)	115
A Study to Evaluate the Efficacy and Safety of KW-0761 in Chinese Subjects With Mycosis Fungoides or Sézary Syndrome Previously Treated With Systemic Therapy

Competitor Landscape

Competing programmes by mechanism and phase

Read-across commentary attached per trial. Phase ordering preserved within each group.

OtherASX peers ›

44 activeexpand ›

KK
A Study to Evaluate the Efficacy and Safety of KW-0761 in Chinese Subjects With Mycosis Fungoides or Sézary Syndrome Previously Treated With Systemic Therapy
Phase 4
Kyowa Kirin China Pharmaceutical Co., Ltd.·Active, not recruiting·Primary completion 12 Aug 2025·NCT06285370
8 sites
23 enrolled

PTX-100n = 115

Prescient Therapeutics·Small Molecule Other·Phase 2·r/r

Design: Open-label, multi-centre, single-arm Phase 2 study (per ClinicalTrials.gov NCT06854653).
Primary endpoint: [ TODO: fill in ]
Dosing: [ TODO: fill in ]
Eligibility: 115 patients (per ClinicalTrials.gov NCT06854653)

A Study to Evaluate the Efficacy and Safety of KW-0761 in Chinese Subjects With Mycosis Fungoides or Sézary Syndrome Previously Treated With Systemic Therapyn = —

Kyowa Kirin China Pharmaceutical Co., Ltd.·—·Phase 4

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

Confirmatory Study of Topical HyBryte™ vs. Placebo for the Treatment of CTCLn = —

Soligenix·—·Phase 3

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

TOtal Skin Electron Beam Therapy (Low-dose) for Tumor Clone Eradication in Early-stage Mycosis Fungoidesn = —

Assistance Publique - Hôpitaux de Paris·—·Phase 3

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

Brentuximab Vedotin in CutAneous T-cell Lymphomas (CTCL): Post-allogeneic Hematopoietic Stem Cell Transplant Maintenancen = —

Assistance Publique - Hôpitaux de Paris·—·Phase 3

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoman = —

National Cancer Institute (NCI)·—·PHASE2/PHASE3

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

Donor Peripheral Stem Cell Transplant in Treating Patients With Advanced Hematologic Cancer or Other Disordersn = —

City of Hope Medical Center·—·Phase 2

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

Nivolumab With or Without Varlilumab in Treating Patients With Relapsed or Refractory Aggressive B-cell Lymphomasn = —

National Cancer Institute (NCI)·—·Phase 2

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

A Trial Assessing the Effect of Pembrolizumab Combined with Radiotherapy in Patients with Relapsed, Refractory, Specified Stages of Cutaneous T-cell Lymphoma (CTCL) Mycosis Fungoides (MF)/Sezary Syndrome (SS)n = —

University College, London·—·Phase 2

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

IPH4102 Alone or in Combination With Chemotherapy in Patients With Advanced T Cell Lymphoman = —

Innate Pharma·—·Phase 2

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

Mogamulizumab Q4week Dosing in Participants With R/R CTCLn = —

Kyowa Kirin, Inc.·—·Phase 2

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

Photopheresis in Early-stage Mycosis Fungoidesn = —

Columbia University·—·Phase 2

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

Pembrolizumab and Mogamulizumab in Advanced-stage, Relapsed/Refractory Cutaneous T-cell Lymphomasn = —

University of Michigan Rogel Cancer Center·—·Phase 2

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

A Phase IIa Clinical Study of Purinostat Mesylate for Injection in Patients With Peripheral T-Cell Lymphoma and Cutaneous T-Cell Lymphoman = —

Chengdu Zenitar Biomedical Technology Co., Ltd·—·Phase 2

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

Anti-CCR4 Monoclonal Antibody (Mogamulizumab) and Total Skin Electron Beam Therapy (TSEB) in Patients With Stage IB-IIB Cutaneous T-Cell Lymphoman = —

European Organisation for Research and Treatment of Cancer - EORTC·—·Phase 2

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

Zanubrutinib and CAR T-cell Therapy for the Treatment of Recurrent or Refractory Aggressive B-cell Non-Hodgkin's Lymphoma or Transformed Indolent B-cell Lymphoman = —

Northwestern University·—·Phase 2

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

A Phase 2 Trial to Assess Safety and Efficacy of Tofacitinib 2% Cream in the Treatment of Cutaneous T-cell Lymphoma (CTCL), Stages IA, IB, and IIAn = —

M.D. Anderson Cancer Center·—·Phase 2

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

Study of Mogamulizumab With DA-EPOCH or CHOEP in Patients With Aggressive T-cell Lymphoman = —

Yale University·—·Phase 2

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

JAK1 Inhibitor Golidocitnib for the Treatment of Relapsed/Refractory Indolent T/NK-cell Lymphomasn = —

Institute of Hematology & Blood Diseases Hospital, China·—·Phase 2

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

Mogamulizumab + Low-Dose Total Skin Electron Beam Tx in Mycosis Fungoides & Sézary Syndromen = —

Stanford University·—·Phase 2

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

Ruxolitinib Maintenance Post-Hematopoietic Stem Cell Transplant T-Cell Lymphoman = —

Jonathan Brammer·—·Phase 2

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

Tafasitamab and Lenalidomide Followed by Tafasitamab and ICE as Salvage Therapy for Transplant Eligible Patients With Relapsed/ Refractory Large B-Cell Lymphoman = —

David Bond, MD·—·Phase 2

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

Effectiveness of Concurrent Ultra-Low-Dose Total-Skin Electron Beam Therapy and Brentuximab Vedotin Given Quarterly Over 12 Months for Patients With Mycosis Fungoidesn = —

M.D. Anderson Cancer Center·—·Phase 2

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

Golcadomide and Rituximab as Bridging Therapy for Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma Before CAR T-cell Therapyn = —

Mayo Clinic·—·Phase 2

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

Pembrolizumab in Combination With Gemcitabine in People With Advanced Mycosis Fungoides or Sézary Syndromen = —

Memorial Sloan Kettering Cancer Center·—·Phase 2

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

Dosing of Brentuximab Vedotin for Mycosis Fungoides, Sezary Syndrome Patientsn = —

Memorial Sloan Kettering Cancer Center·—·Phase 2

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

TTI-622 in Combination With Pembrolizumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoman = —

Mayo Clinic·—·Phase 2

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancersn = —

National Cancer Institute (NCI)·—·Phase 2

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

Ultra Low Dose Radiation Therapy in Treating Patients With Mycosis Fungoidesn = —

M.D. Anderson Cancer Center·—·Phase 2

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

A Phase 2 Study of PTX 100 in Patients With Relapsed/Refractory CTCLn = —

Prescient Therapeutics, Ltd.·—·Phase 2

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

Amping up With PemJAKn = —

Seda S. Tolu·—·Phase 2

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

SGN-35 in CD30-positive Lymphoproliferative Disorders (ALCL), Mycosis Fungoides (MF), and Extensive Lymphomatoid Papulosis (LyP)n = —

M.D. Anderson Cancer Center·—·Phase 2

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

Pembrolizumab and Brentuximab Vedotin in Subjects With Relapsed/Refractory T-cell Lymphoman = —

Yale University·—·Phase 2

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

Extracorporeal Photopheresis and Mogamulizumab for the Treatment of Erythrodermic Cutaneous T Cell Lymphoman = —

City of Hope Medical Center·—·Phase 2

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

A Study of VG712 in Patients With Mycosis Fungoidesn = —

Virogen Biotechnology Inc.·—·Phase 2

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

Pembrolizumab and Pralatrexate in Treating Patients With Relapsed or Refractory Peripheral T-Cell Lymphomasn = —

City of Hope Medical Center·—·PHASE1/PHASE2

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

CD7 CAR T-Cell Therapy for r/r T-cell Lymphomasn = —

Beijing GoBroad Hospital·—·PHASE1/PHASE2

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

A First-in-Human Study of HLA-Partially to Fully Matched Allogenic Cryopreserved Deceased Donor Bone Marrow Transplantation for Patients With Hematologic Malignanciesn = —

Ossium Health, Inc.·—·PHASE1/PHASE2

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

CD5 CAR T-Cell Therapy for r/r T-cell Lymphomasn = —

Beijing GoBroad Hospital·—·PHASE1/PHASE2

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

Durvalumab With or Without Lenalidomide in Treating Patients With Relapsed or Refractory Cutaneous or Peripheral T Cell Lymphoman = —

City of Hope Medical Center·—·PHASE1/PHASE2

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomasn = —

Dren Bio·—·PHASE1/PHASE2

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

A Study to Assess the Safety, Tolerability, Efficacy, and Drug Levels of BMS-986369 (Golcadomide) in Participants With Relapsed or Refractory T-cell Lymphomas in Japan (GOLSEEK-3)n = —

Bristol-Myers Squibb·—·PHASE1/PHASE2

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

Study of Pembrolizumab (MK-3475) in Combination With Romidepsinn = —

M.D. Anderson Cancer Center·—·PHASE1/PHASE2

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

Aclarubicin Plus Cyclophosphamide, Vincristine, and Prednisone (CAOP) in Patients With Previously Treated Cutaneous T-cell Lymphoman = —

Shanghai Jiao Tong University School of Medicine·—·PHASE1/PHASE2

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

Duvelisib and Venetoclax in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)n = —

Jonsson Comprehensive Cancer Center·—·PHASE1/PHASE2

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —